---
document_datetime: 2023-09-21 21:42:15
document_pages: 22
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zonegran-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zonegran-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 14.3173886
conversion_datetime: 2025-12-14 21:39:20.539189
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Zonegran

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                   |
|----------------------|----------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/3152/ 202203   | Periodic Safety Update EU Single assessment - zonisamide | 15/12/2022                          | 15/02/2023                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3152/202203. |
| IAIN/0105/G          | This was an application for a group of variations.       | 12/10/2022                          | 15/02/2023                                  | SmPC, Annex II and PL            |                                                                                                                                           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|        | B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.d.2.a - Change in test procedure for the finished   |            |            |                        |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| T/0103 | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13/01/2022 | 27/01/2022 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| N/0102             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                     | 01/06/2021   | 27/01/2022   | PL                  |                                                                                                                                           |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0101            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                        | 01/03/2021   | 27/01/2022   | Annex II and PL     |                                                                                                                                           |
| IB/0100            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                        | 29/01/2021   | n/a          |                     |                                                                                                                                           |
| PSUSA/3152/ 202003 | Periodic Safety Update EU Single assessment - zonisamide                                                                                                                                                                                                                                             | 12/11/2020   | 11/01/2021   | SmPC and PL         | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3152/202003. |
| IA/0099/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 17/07/2020   | n/a          |                     |                                                                                                                                           |
| IG/1263            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                               | 24/06/2020   | 11/01/2021   | Annex II and PL     |                                                                                                                                           |
| IG/1260/G          | This was an application for a group of variations. A.1 - Administrative change - Change in the name                                                                                                                                                                                                  | 24/06/2020   | 11/01/2021   | SmPC, Labelling and |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                    | and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                             |            |     | PL   |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-----------------------------------|
| PSUSA/3152/ 201903 | Periodic Safety Update EU Single assessment - zonisamide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 31/10/2019 | n/a |      | PRAC Recommendation - maintenance |
| IB/0095/G          | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.e.z - Change in container closure system of the Finished Product - Other variation B.II.e.3.b - Change in test procedure for the immediate packaging of the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.z - Change in the specification parameters | 30/09/2019 | n/a |      |                                   |

<div style=\"page-break-after: always\"></div>

|                    | finished product - Other variation                                                                                                                                                                                                                                                                                                                                                           |            |            |                        |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0093            | C.I.7.a - Deletion of - a pharmaceutical form                                                                                                                                                                                                                                                                                                                                                | 19/02/2019 | 24/10/2019 | SmPC, Labelling and PL |                                   |
| IG/1044/G          | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 22/01/2019 | n/a        |                        |                                   |
| IG/1008            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                       | 30/11/2018 | 24/10/2019 | Annex II and PL        |                                   |
| PSUSA/3152/ 201803 | Periodic Safety Update EU Single assessment - zonisamide                                                                                                                                                                                                                                                                                                                                     | 31/10/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| T/0090             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                          | 30/08/2018 | 21/09/2018 | SmPC, Labelling and PL |                                   |
| IA/0089            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                | 30/07/2018 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0088          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   | 06/07/2018   | n/a        |             |                                                                                                                                           |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/3152/ 201703 | Periodic Safety Update EU Single assessment - zonisamide                                                                                                                                                                                 | 09/11/2017   | 08/01/2018 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3152/201703. |
| N/0086             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                         | 16/11/2017   | 21/09/2018 | PL          |                                                                                                                                           |
| IA/0084            | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                   | 22/05/2017   | n/a        |             |                                                                                                                                           |
| IA/0082            | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                   | 07/04/2017   | n/a        |             |                                                                                                                                           |
| IA/0081            | B.I.c.2.a - Change in the specification parameters and/or limits of the immediate packaging of the AS - Tightening of specification limits                                                                                               | 07/04/2017   | n/a        |             |                                                                                                                                           |
| IB/0080            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                           | 19/01/2017   | 08/01/2018 | SmPC and PL |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| PSUSA/3152/ 201603   | Periodic Safety Update EU Single assessment - zonisamide                                                                                                                                                                                     | 10/11/2016   | 04/01/2017   | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3152/201603.   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0078              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 24/06/2016   | 04/01/2017   | SmPC, Labelling and PL |                                                                                                                                             |
| IB/0077              | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                | 25/04/2016   | n/a          |                        |                                                                                                                                             |
| PSUSA/3152/ 201503   | Periodic Safety Update EU Single assessment - zonisamide                                                                                                                                                                                     | 08/10/2015   | n/a          |                        | PRAC Recommendation - maintenance                                                                                                           |
| IA/0076              | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 06/07/2015   | n/a          |                        |                                                                                                                                             |
| PSUV/0073            | Periodic Safety Update                                                                                                                                                                                                                       | 09/10/2014   | n/a          |                        | PRAC Recommendation - maintenance                                                                                                           |
| IA/0074              | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                        | 19/08/2014   | n/a          |                        |                                                                                                                                             |
| II/0072              | To add a new active substance manufacturer supported by an ASMF (Active Substance Master File) for the manufacture of hard capsules.                                                                                                         | 26/06/2014   | n/a          |                        |                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF                                                                                                                                                    |            |            |                       |                                                                                                                                    |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------|
| IB/0071   | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                             | 28/05/2014 | n/a        |                       |                                                                                                                                    |
| IA/0070   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                          | 11/10/2013 | n/a        |                       |                                                                                                                                    |
| II/0065   | Extension of Indication for adjunctive treatment of partial seizures with or without secondary generalisation in adult patients to include paediatric patients aged 6 years and above. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 25/07/2013 | 02/10/2013 | SmPC, Annex II and PL | The CHMP variation assessment report will be published as part of the EPAR, following review/deletion of confidential information. |
| IG/0345   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                       | 03/09/2013 | n/a        |                       |                                                                                                                                    |
| IAIN/0068 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                        | 29/04/2013 | n/a        |                       |                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| II/0066/G   | This was an application for a group of variations.   | 21/02/2013   | 21/02/2013   |
|-------------|------------------------------------------------------|--------------|--------------|

<div style=\"page-break-after: always\"></div>

|         | size ranges) of the finished product - Downscaling down to 10-fold B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new tests and limits B.II.e.1.z - Change in immediate packaging of the finished product - Other variation                                                                                                                                                                         |            |            |                       |                                                                                                                                                                                                                                                                                                                                              |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0067 | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                                                                                                    | 13/02/2013 | 02/10/2013 | SmPC and PL           | Update of section 4.8 to include hypersensitivity-type pneumonitis as a result of the final assessment report for PSUR 09. The MAH also updated the contact details of the local representatives for Belgium and Luxembourg.                                                                                                                 |
| II/0063 | Update of sections 4.8 of the SmPC in order to include alopecia as a 'common' adverse reaction as requested by the CHMP consequent to the detection of a possible signal for alopecia associated with Zonegran. The Package Leaflet is updated to amend the changes; 'hair loss' has been added as common side effect. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 21/06/2012 | 20/07/2012 | SmPC and PL           | The MAH took the opportunity to update the Product Information of Zonegran with the insertion of alopecia as a common adverse reaction. To support the changes a review of the safety data arising from clinical trials, serious/non- serious post-marketing spontaneous reports and reports from literature, has been performed by the MAH. |
| II/0059 | Extension of the approved indication of adjunctive treatment of partial seizures with or without secondary generalisation in adults to include monotherapy in adults with newly diagnosed epilepsy.                                                                                                                                                                                                                                                                           | 24/05/2012 | 27/06/2012 | SmPC, Annex II and PL | Please refer to the CHMP AR report for this extension variation.                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0064/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of                                                                                                                                                         | 15/05/2012 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0060   | Update of section 4.8 of the SmPC in order to change in the frequency of pruritus from very rare to common and to add information relating to the increased frequency of certain conditions in the elderly population compared to the adult population, i.e. pruritus and oedema peripheral. Consequentially, the PL is updated as well. Minor editorial changes have been introduced in Annex II. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 16/02/2012 | 30/03/2012 | SmPC, Annex II and PL | The MAH submitted a Type II Variation following a pooled analysis of data in use in the elderly of zonisomide to assess the fulfilment of FUM-005. The pooled data analysis demonstrated that pruritus and oedema peripheral were overall more frequent in the elderly. Data on the adverse event pruritus has also shown that it should be reclassified as a common adverse event rather than a rare adverse event, as previously classified. |
| IB/0061   | C.I.3.a - Implementation of change(s) requested                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16/01/2012 | 30/03/2012 | SmPC and PL           | Update of section 4.8 of the SmPC to include Drug-Induced                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     | Hypersensitivity Syndrome (DIHS) and Drug rash with eosinophilia and systemic symptoms (DRESS) following assessment of PSUR 8. In addition, the local representative section has been updated and minor grammatical corrections have been included in the Latvian and Portuguese Product Information.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0062/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.III.1.b.2 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. | 19/12/2011 | n/a |                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0058/G | This was an application for a group of variations. C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV                                                                                                                   | 06/07/2011 | n/a        | Annex II    |                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0057   | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                                                                                                                   | 20/06/2011 | n/a        | SmPC and PL | Following a review of bone disorders associated with the use of Zonegran (FUM 32) the CHMP requested the MAH to update an existing warning in section 4.4 of the SPC to reflect the risk of osteopenia. In addition, the MAH has taken this opportunity to update the local representatives section in the Package Leaflet and to introduce minor linguistic corrections. |
| II/0054/G | This was an application for a group of variations. To delete one significant in-process control(IPC 3) and two non-significant in-process controls (IPC4 and IPC6) in the manufacturing of Zonegran capsules. B.II.b.5.d - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of an in-process test which may have a significant effect on the overall quality of the finished product B.II.b.5.c - Change to in-process tests or limits | 23/09/2010 | 29/09/2010 |             |                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | during the manufacture of the finished - Deletion of a non-significant in-process test                                                                                                                                                                                                                                                                                                                                                              |            |            |                        | applied product       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------|
| IB/0056   | B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                          | 24/08/2010 | n/a        |                        |                       |
| IA/0055/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of | 05/08/2010 | n/a        | Annex II               | the pharmacovigilance |
| X/0048    | Addition of a new pharmaceutical form (orodispersible tablets) in the following strengths 25 mg, 50 mg, 100 mg and 300 mg. Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                                                                                                                                                                                                            | 20/05/2010 | 27/07/2010 | SmPC, Labelling and PL |                       |
| IB/0053   | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                                                                          | 16/03/2010 | n/a        | SmPC and PL            |                       |

<div style=\"page-break-after: always\"></div>

| R/0050 IB/0052   | Renewal of the marketing authorisation. IA_37_a_Change in the specification of the finished                                                                                                                                                                                                                                              | 22/10/2009 16/11/2009   | 21/12/2009 n/a   | SmPC, Annex II, Labelling and PL   | Based on the review of the available information, the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers the benefit/risk profile of Zonegran continues to be favorable. The CHMP is also of the opinion that the renewal can be granted with unlimited validity. The MAH should continue to submit yearly PSURs.                 |
|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------|------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0051          | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms                                                                                              | 05/08/2009              | n/a              |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0044          | Update of sections 4.4 and 4.8 of the Summary of Products Characteristics and sections 2 and 4 of the Package Leaflet to include information relating to metabolic acidosis and renal tubular acidosis at the request of the CHMP. In addition, the name of the Portuguese local representative in the Package Leaflet has been updated. | 29/05/2009              | 07/07/2009       | SmPC and PL                        | Further to the assessment of a Cumulative review of Pharmacovigilance data relating to serious renal adverse events as well as serious hypersensitivity, skin and haematological adverse events (covering the period 1 April 2005 to 30 June 2008) it was concluded that metabolic acidosis is associated with Zonegran treatment. This metabolic acidosis is caused by renal bicarbonate loss due to the inhibitory effect of Zonegran on carbonic anhydrase. |

<div style=\"page-break-after: always\"></div>

|         | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                      |            |            |                        | The amounts of which bicarbonate is decreased are usually small. The risk of induced metabolic acidosis appears to be more frequent and severe in younger patients. In addition, a signal of renal tubular acidosis was detected in the EudraVigilance database and following the request of CHMP the term was included in the listing of adverse reactions associated with Zonegran.     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0049 | IA_26_a_Change in the specification of immediate packaging - tightening of specification limits IB_29_b_Change in qual./quant. composition of immediate packaging - all other pharm. forms                                                                            | 11/06/2009 | n/a        | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0043 | Quality changes                                                                                                                                                                                                                                                       | 29/05/2009 | 04/06/2009 |                        |                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0046 | IB_25_a_01_Change to comply with Ph. - compliance with EU Ph. - active substance                                                                                                                                                                                      | 26/03/2009 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0047 | IA_01_Change in the name and/or address of the marketing authorisation holder                                                                                                                                                                                         | 16/03/2009 | n/a        | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0045 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                                                                                                                      | 16/02/2009 | n/a        | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0041 | Update of the section 4.8 of the Summary of Product Characteristics and sections 2 and 4 of the Package Leaflet to include 'toxic epidermal necrolysis' (TEN) under the System Organ Class \"Skin and subcutaneous tissue disorders\", as a \"very rare\" adverse effect. | 18/12/2008 | 11/02/2009 | SmPC and PL            | Following assessment of a Cumulative Review covering the period 1 April 2005 to 31 March 2008 (submitted with the 5th PSUR), the CHMP requested the MAH to amend the product information (PI) to include the adverse event TEN in the section 4.8 of the Summary of Product Characteristics (SPC). The section has been amended to include TEN. Sections 2 and 4 of the PIL were modified |

<div style=\"page-break-after: always\"></div>

|         | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                                                                      |            |            |             | accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0040 | Update to the section 4.4 of the Summary of Product Characteristics and the relevant sections of the Package Leaflet following the CHMP assessment of signal of suicidal ideation and behaviour in patients treated with antiepileptics. The MAH took this opportunity to update the Greek and Maltese local representatives in the Package Leaflet. Update of Summary of Product Characteristics and Package Leaflet | 18/12/2008 | 11/02/2009 | SmPC and PL | Due to concerns over the potential risk of suicidal thoughts and behaviour in association with the use of antiepileptics, data available from randomized placebo controlled trials and from the post-marketing phase for this class of medicines was considered by the CHMP. Overall, despite the small number of events seen in the clinical trials and the lack of a statistically significant increased risk of suicidal behaviour, the analysis of randomized placebo controlled trials of antiepileptic drugs did not exclude the possibility of an increased risk. Therefore, the CHMP considered it necessary to update section 4.4 of the SPC and section 2 of the PL with information regarding suicidal ideation and behaviour. |
| IA/0042 | IA_25_b_01_Change to comply with Ph. - compliance with EU Ph. update - active substance                                                                                                                                                                                                                                                                                                                               | 08/12/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0039 | IA_37_a_Change in the specification of the finished product - tightening of specification limits                                                                                                                                                                                                                                                                                                                      | 12/09/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IA/0038 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                                                                                              | 17/06/2008 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0031 | Update of sections 4.4 and 4.8 of the Summary of Product Characteristics and relevant sections of the Package Leaflet following the assessment of the 4th PSUR.                                                                                                                                                                                                                                                       | 21/02/2008 | 31/03/2008 | SmPC and PL | The product information has been amended, at the request of CHMP, to strengthen the warnings on allergic reactions to sulphonamides, and the higher incidence of Stevens- Johnson syndrome (SJS) and Drug Induced Hypersensitivity Syndrome (DIHS) in the elderly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         | Update of Summary of Product Characteristics and Package Leaflet                                 |            |            |    | The overall undesirable effects inluded in the SPC and PL have also been reviewed and the following terms have been included: constipation, indigestion, fatigue, flu-like symptoms, slowed thoughts, involuntary movement of the eyes, abnormal skin sensation (pins and needles), tremor, feeling anxious or emotional, blood creatinine increased, ecchymosis (a small bruise caused by blood leaking from broken blood vessels in the skin), status epilepticus (prolonged or repeated seizures) and decreased blood levels of bicarbonate (a substance that prevents blood from becoming acidic). In addition, the undesirable effects frequencies have been amended for insomnia, psychotic disorder (strange or unusual thoughts) and kidney stones.   |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0037 | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                       | 27/03/2008 | n/a        |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0036 | IA_08_a_Change in BR/QC testing - repl./add. of batch control/testing site                       | 27/03/2008 | n/a        |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0034 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                         | 20/02/2008 | n/a        |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0033 | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer              | 15/02/2008 | n/a        |    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0032 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing | 15/02/2008 | n/a        | PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0029 | Update of the Package Leaflet following a \"User\" Test.                                           | 15/11/2007 | 18/12/2007 | PL | The MAH performed a \"User\" Test to ensure that the Package Leaflet of Zonegran was clear, legible and easy to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|         | Update of Package Leaflet                                                                                                                                                                                        |            |            |                        | use. The Package Leaflet has been extensively revised to reflect the recommendation of the test results.                                                                                                                                                                                                                |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0030 | IA_34_a_01_Change in colour/flavour - Reduction or deletion: colouring system IB_34_b_01_Change in colour/flavour - Increase or addition: colouring system                                                       | 14/12/2007 | n/a        |                        |                                                                                                                                                                                                                                                                                                                         |
| II/0026 | Update of section 4.4 of the Summary of Product Characteristics. Update of Summary of Product Characteristics                                                                                                    | 20/09/2007 | 29/10/2007 | SmPC                   | Section 4.4 of the Summary of Product Characteristics (SPC) was amended to strengthen warnings on Stevens- Johnson syndrome and rash.                                                                                                                                                                                   |
| II/0025 | Update of section 4.5 of the Summary of Product Characteristics (SPC) and minor changes throughout the labelling and Package Leaflet Update of Summary of Product Characteristics, Labelling and Package Leaflet | 20/09/2007 | 29/10/2007 | SmPC, Labelling and PL | Following the submission of interaction studies with zonisamide section 4.5 of the SPC has been updated. In particular, caution is advised when starting or stopping zonisamide treatment or changing the zonisamide dose in patients who are also receiving drugs which are P-gp substrates (e.g. digoxin, quinidine). |
| N/0027  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                 | 11/09/2007 | n/a        | PL                     |                                                                                                                                                                                                                                                                                                                         |
| IA/0028 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                         | 05/09/2007 | n/a        |                        |                                                                                                                                                                                                                                                                                                                         |
| IA/0024 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                         | 30/05/2007 | n/a        |                        |                                                                                                                                                                                                                                                                                                                         |
| IA/0023 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                         | 04/05/2007 | n/a        |                        |                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IB/0022   | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                                                                                                                                 | 23/04/2007   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0021   | Following the assessment of the second PSUR, the MAH updated the warnings on Stevens-Johnson Syndrome (in section 4.4 of SPC) and on the use of Zonegran during preganancy (in section 4.6 of SPC) and included a reference to aggression, anger and suicidal attempt (in section 4.8 of SPC). The PL was updated accordingly. Update of Summary of Product Characteristics, Labelling and Package Leaflet | 22/02/2007   | 28/03/2007 | SmPC, Labelling and PL | The current warning regarding the occurrence of serious rashes in association with Zonegran therapy, including cases of Stevens-Johnson syndrome, has been highlighted in bold and in a box in the product information. The warnings regarding the use of antiepileptic medication during pregnancy and the need of adequate contraception have been tightened and the risk of birth defect in children of women taking anti-epileptic drugs has been highlighted. The product information has also been updated to make reference to anger, aggression and suicide attempt as possible side effects of Zonegran. |
| IB/0020   | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                                                                                                                                                                                                                                                                                   | 12/01/2007   | 12/01/2007 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0019   | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                                                                                                                                                                                                                                                                                   | 12/01/2007   | 12/01/2007 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0018   | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size                                                                                                                                                                                                                                                                                                                    | 24/11/2006   | 24/11/2006 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0016   | Update of section 4.4 of the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                           | 27/07/2006   | 07/09/2006 | SmPC                   | Following the evaluation of the first PSUR, the MAH updated the product information to omit the word \"isolated\" in section 4.4 in relation to the occurrence of agranulocytosis                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|         | Update of Summary of Product Characteristics                                                       |            |            |                        | and Stevens Johnson syndrome. Stevens Johnson syndrome and agranulocytosis remain as very rare events.   |
|---------|----------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------|
| II/0015 | Quality changes                                                                                    | 27/07/2006 | 03/08/2006 |                        |                                                                                                          |
| IB/0014 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                         | 05/04/2006 | n/a        | SmPC                   |                                                                                                          |
| N/0013  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)   | 10/02/2006 | n/a        | PL                     |                                                                                                          |
| IA/0012 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) | 11/01/2006 | n/a        |                        |                                                                                                          |
| IA/0011 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                           | 21/09/2005 | n/a        |                        |                                                                                                          |
| IA/0010 | IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms            | 04/08/2005 | n/a        |                        |                                                                                                          |
| IA/0009 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                           | 10/06/2005 | n/a        |                        |                                                                                                          |
| IB/0008 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size           | 26/04/2005 | 26/04/2005 | SmPC, Labelling and PL |                                                                                                          |
| IB/0007 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size           | 26/04/2005 | 26/04/2005 | SmPC, Labelling and PL |                                                                                                          |
| IB/0006 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size           | 26/04/2005 | 26/04/2005 | SmPC, Labelling and    |                                                                                                          |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                  |            |            | PL                               |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| IB/0005 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size         | 26/04/2005 | 26/04/2005 | SmPC, Labelling and PL           |
| IB/0004 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size         | 26/04/2005 | 26/04/2005 | SmPC, Labelling and PL           |
| IA/0003 | IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size          | 18/04/2005 | 18/04/2005 | SmPC, Annex II, Labelling and PL |
| IA/0002 | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer              | 18/04/2005 | n/a        |                                  |
| IA/0001 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing | 18/04/2005 | n/a        | Annex II and PL                  |